A Randomized, Double-blind, Controlled Clinical Study of Human Umbilical Cord Mesenchymal Stem Cell(UC-MSC)Delayed Renal Chronic Kidney Disease(CKD3、4 )
试验速览
- 阶段
- 1 期
- 入组人数
- 44
- 试验地点
- 1
- 主要终点
- Number of participants with treatment-related adverse events as assessed by SPSS 23.0 and Graphpad prism 6
研究概览
简要总结
The chronic kidney disease is caused by renal structural and functional impairment for more than 3 months due to various causes, including normal and abnormal glomerular filtration rate (GFR), abnormal blood, urine, and imaging findings, or an unexplained decline in GFR (<60 ml/min). Recent years, the incidence of chronic kidney disease has increased year by year worldwide, the incidence of CKD is 8% to 16% in the world's total population. chronic kidney disease has become an important public health problem in China and even the world.
Summarizing the basic and clinical studies at home and abroad, inflammatory factors such as inflammatory chemokines, cytokines, and reactive oxygen species interact with fibrosis factors such as mesangial cells, fibroblasts, and fibroblast activation, which are the root causes of the progression of CKD and the formation of tubular interstitial fibrosis and glomerular sclerosis and developing into end-stage renal disease.
Current treatments for chronic kidney disease are very limited, and to be precise, there is currently no cure for chronic kidney disease, nor is there a proven way to improve the kidneys survive after acute kidney injury (AKI). The progression of the disease itself can only be delayed as much as possible by changing the diet, controlling related complications with oral medications (such as hypertension, hyperlipidemia, nephropathy, etc.), and actively controlling blood glucose and glycosylated hemoglobin levels in patients with diabetes. For patients with stage CKD5 and more severe, renal replacement therapy is recommended, including hemodialysis and peritoneal dialysis, but there are many complications in both dialysis methods, such as narrowing of the internal fistula, occlusion, catheter infection, peritonitis, etc. Kidney transplantation may be considered when economic conditions permit and there is a matching kidney source, but kidney transplant surgery is riskier. The above treatment methods have brought a heavy burden to patients and social medicine. In order to seek innovative and effective strategies to cultivate the limited regenerative capacity of the kidneys and reverse renal fibrosis, the mesenchymal stem cells (MSCs) with tissue regenerative potential and immunomodulatory functions have brought new ideas and hopes for the prevention and treatment of chronic kidney disease.
详细描述
The chronic kidney disease is caused by renal structural and functional impairment for more than 3 months due to various causes, including normal and abnormal glomerular filtration rate (GFR), abnormal blood, urine, and imaging findings, or an unexplained decline in GFR (<60 ml/min). Recent years, the incidence of chronic kidney disease has increased year by year worldwide, the incidence of CKD is 8% to 16% in the world's total population. The incidence of CKD and the primary causative factors vary from country to country and region, and the idemiological survey led by Peking University Hospital shows that the prevalence of CKD in China is 10.8% , the primary causative factor is glomerulonephritis, but as the incidence of hypertension and diabetes rises year by year, and the world will have more than 10 million people a year have acute kidney injury, the proportion of chronic kidney disease in the long-term course of the above population will be much higher than the normal population, chronic kidney disease has become an important public health problem in China and even the world.
Summarizing the basic and clinical studies at home and abroad, inflammatory factors such as inflammatory chemokines, cytokines, and reactive oxygen species interact with fibrosis factors such as mesangial cells, fibroblasts, and fibroblast activation, which are the root causes of the progression of CKD and the formation of tubular interstitial fibrosis and glomerular sclerosis and developing into end-stage renal disease.
Current treatments for chronic kidney disease are very limited, and to be precise, there is currently no cure for chronic kidney disease, nor is there a proven way to improve the kidneys survive after acute kidney injury (AKI). The progression of the disease itself can only be delayed as much as possible by changing the diet, controlling related complications with oral medications (such as hypertension, hyperlipidemia, nephropathy, etc.), and actively controlling blood glucose and glycosylated hemoglobin levels in patients with diabetes. For patients with stage CKD5 and more severe, renal replacement therapy is recommended, including hemodialysis and peritoneal dialysis, but there are many complications in both dialysis methods, such as narrowing of the internal fistula, occlusion, catheter infection, peritonitis, etc. The presence of the above complications will reduce the service life of the patient's dialysis pathway while also causing blows to other organ systems. Kidney transplantation may be considered when economic conditions permit and there is a matching kidney source, but kidney transplant surgery is riskier, and the average survival of transplanted kidneys is currently 12 years calculated by the American National Kidney Foundation, during this period, patients need to take anti-rejection drugs uninterruptedly, and these drugs (such as tacrolimus, cyclosporine, etc.) can also greatly damage the kidney organs and function. The above treatment methods have brought a heavy burden to patients and social medicine. In order to seek innovative and effective strategies to cultivate the limited regenerative capacity of the kidneys and reverse renal fibrosis, the mesenchymal stem cells (MSCs) with tissue regenerative potential and immunomodulatory functions have brought new ideas and hopes for the prevention and treatment of chronic kidney disease.
Progression in chronic kidney disease includes tubular interstitial fibrosis and glomerulosclerosis:
- Tubular interstitial fibrosis is mainly characterized by tubular hypermetabolism, tubular epithelial-interstitial transition, and hypoxic damage to the renal interstitium, which eventually leads to infiltration of inflammatory cells, abnormal increase in extracellular matrix components in renal tissue, and disappearance of parenchymal cells. 2)Glomerulosclerosis is the outcome of excessive response of glomerular constituent related cells to injury, including structural changes, cells' gradual atrophy, shedding, apoptosis of cells, loss of anticoagulant properties, and increased expression of pro-inflammatory factors and pro-fibrosis factors; Proliferation of mesangial cells, mesangial differentiation into myofibroblasts, causing collagen III to be deposited in the renal units, leading to irreversible hardening of the glomeruli; The number of pinus process cells decreases, the skeleton retracts or flattens, and inflammatory cell aggregation of chemokines is released, while synthetic cytokines and growth factors further aggravate globules capillary sclerosis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with clinical diagnosis of chronic kidney disease (CKD) and stage 3 and stage 4 (GFR 15-60 ml/min) of CKD (American Kidney Disease Foundation stage)
- •Agree to sign the informed consent form at the same time by means of participation of the pilot group
- •Age between 18-65 years old
排除标准
- •Patients who are taking immunosuppressants or have been taking them within a month
- •Patients with a 30% increase in creatinine in the past 3 months and who are about to undergo dialysis
- •Suffering from severe heart, respiratory insufficiency, viral hepatitis, and sexually transmitted diseases
- •Hypersensitivity to stem cells themselves or stem cell-related media
- •Patients with recent bacterial, viral, or fungal infections
- •Have a history of tumors or are currently suffering from tumor conditions
- •Pregnant or breastfeeding
- •Have participated in drug-related clinical trials in the past two months
- •Any form of substance abuse, mental illness, and other conditions that researchers believe may affect the effectiveness of the test or the patient's physical health
研究组 & 干预措施
Comparator
Comparator participants will receive saline solution
干预措施: Saline solution (Biological)
Experimental
MSCs Participants will receive HUC-MSCs
干预措施: UC-MSC (Biological)
结局指标
主要结局
Number of participants with treatment-related adverse events as assessed by SPSS 23.0 and Graphpad prism 6
时间窗: Through study completion, an average of 13 months
Collecting and comparing the number and severity of participants with skin reactions, fever, infection, allergic reactions, etc. in the two groups.
Change of GFR
时间窗: baseline, 6-month after 2nd treatment, 12-month after 2nd treatment
GFR decrease at 2.5ml/min/year or more from baseline
Incidence of Treatment-Serious Adverse Events as assessed by SPSS 23.0 and Graphpad prism 6
时间窗: Through study completion, an average of 13 months
To observe the incidence of serious adverse events,such as fatal cardiovascular and cerebrovascular disease, tumor, organ failure, severe infection.
次要结局
- IgG(2 weeks after the first treatment, 1 month, 3 months, 6 months and 9 months, 12 months, 18 months, 24 months after the second treatment)
- IgM(2 weeks after the first treatment, 1 month, 3 months, 6 months and 9 months, 12 months, 18 months, 24 months after the second treatment)
- C3(2 weeks after the first treatment, 1 month, 3 months, 6 months and 9 months, 12 months, 18 months, 24 months after the second treatment)
- CRP(2 weeks after the first treatment, 1 month, 3 months, 6 months and 9 months, 12 months, 18 months, 24 months after the second treatment)
- C4(2 weeks after the first treatment, 1 month, 3 months, 6 months and 9 months, 12 months, 18 months, 24 months after the second treatment)
- Albumin(2 weeks after the first treatment, 1 month, 3 months, 6 months and 9 months, 12 months, 18 months, 24 months after the second treatment)
- Carotid ultrasound(Baseline, 3 months, 6 months and 9 months, 12 months, 18 months, 24 months after the second treatment)
- Peripheral hemolymocyte subsets(2 weeks after the first treatment, 1 month, 3 months, 6 months and 9 months, 12 months, 18 months, 24 months after the second treatment)
- IL-6(2 weeks after the first treatment, 1 month, 3 months, 6 months and 9 months, 12 months, 18 months, 24 months after the second treatment)
- Urine protein(2 weeks after the first treatment, 1 month, 3 months, 6 months and 9 months, 12 months, 18 months, 24 months after the second treatment)
- IgA(2 weeks after the first treatment, 1 month, 3 months, 6 months and 9 months, 12 months, 18 months, 24 months after the second treatment)
- Urine RBC(2 weeks after the first treatment, 1 month, 3 months, 6 months and 9 months, 12 months, 18 months, 24 months after the second treatment)
- 24-hour urine protein(2 weeks after the first treatment, 1 month, 3 months, 6 months and 9 months, 12 months, 18 months, 24 months after the second treatment)
- Urine albumin/creatinine(2 weeks after the first treatment, 1 month, 3 months, 6 months and 9 months, 12 months, 18 months, 24 months after the second treatment)
- iPTH+1,25-VitD3(Baseline, 2nd treatment, 1 months, 3 months, 6 months and 9 months, 12 months, 18 months, 24 months after the second treatment)
- Heart ultrasound(Baseline, 3 months, 6 months and 9 months, 12 months,18 months, 24 months after the second treatment)
- Electrolytes(2 weeks after the first treatment, 1 month, 3 months, 6 months and 9 months, 12 months, 18 months, 24 months after the second treatment)
- Hemoglobin(2 weeks after the first treatment, 1 month, 3 months, 6 months and 9 months, 12 months, 18 months, 24 months after the second treatment)
- NT-proBNP(Baseline, 2nd treatment, 1 months, 3 months, 6 months and 9 months, 12 months, 18 months, 24 months after the second treatment)
研究者
Gang Xu
Principle Investigator, Clinical Professor
Tongji Hospital
